A Phase 4 interventional study of Setmelanotide in Bardet Biedl Syndrome (BBS), Bardet Biedl Syndrome and Bardet-Biedl Syndrome (BBS), sponsored by Tom Hühne. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Tom Hühne · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Bardet-Biedl syndrome (BBS) and other rare disorders associated with impairment of the melanocortin-4 receptor (MC4R) pathway are characterized by severe early-onset obesity, hyperphagia, and substantial morbidity. Setmelanotide, an MC4R agonist, is approved in Europe for selected genetic obesity disorders and reimbursed in Germany for eligible patients. This study aims to evaluate the effectiveness, safety, treatment persistence, metabolic outcomes, and patient-reported outcomes of Setmelanotide under real-world conditions. The registry is designed to allow future inclusion of additional MC4R agonists as they become approved and clinically available. The study will primarily be conducted at University Hospital Essen and will collect longitudinal routine clinical data from pediatric and adult patients receiving MC4R agonist therapy according to approved indications.
The MC4R signaling pathway is a key regulator of appetite and energy balance. Genetic defects affecting this pathway lead to severe obesity syndromes including Bardet-Biedl syndrome and other rare monogenic obesity disorders. Although pivotal clinical trials demonstrated efficacy of Setmelanotide, evidence from routine clinical care remains limited. This study seeks to characterize treatment outcomes in everyday clinical practice, including changes in body weight, BMI, hyperphagia, metabolic parameters, quality of life, treatment adherence, and adverse events. Patients receiving approved MC4R agonist therapy will be followed prospectively. Data will be collected during routine outpatient visits and include anthropometric, clinical, laboratory, and patient-reported measures. The study infrastructure is intended to serve as a platform for future MC4R agonists approved for severe genetic obesity disorders.
This is the only study on the registry with Tom Hühne as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients receiving approved MC4 receptor agonists according to licensed indications and routine clinical practice.
Drug: Setmelanotide
Administration according to approved product labeling and treating physician discretion
Percent change in BMI z-score
Relative change in BMI z-Score after initiation of MC4 receptor agonist therapy
Time frame: Baseline to 12/24/36/48/60/72 months
Impact on lipid profile
Changes in lipid profile measured by cholesterol blood levels
Time frame: Baseline to 12/24/36/48/60/72 months
Change in Hepatic Fat Attenuation
Hepatic Fat Attenuation will be measured by ultrasound Attenuation imaging across different time points
Time frame: Baseline to 12/24/36/48/60/72 months
Life quality
Patient-reported quality of life using e.g. the "Impact of weight on Quality of life"-questionnaire (IWQOL). The assessment is based on a scale from 0 to 100, with 100 representing the best possible weight-related quality of life.
Time frame: Baseline to 12/24/36/48/60/72 months
Safety and Tolerability
Incidence of adverse events, serious adverse events and treatment discontinuations and reasons for it
Time frame: Baseline to 12/24/36/48/60/72 months
Cognitive changes
Neurocognitive impairment is common in Bardet-Biedl Syndrome. Wechsler Intelligence Scale for Children - Fourth Edition (WISC-IV) for children and Wechsler Adult Intelligence Scale (WAIS) for adults are performed to investigate cognition before and after intervention.
Time frame: Baseline to 12/24/36/48/60/72 months
Functional brain connectivity
Newly diagnosed patients undergo non-invasive functional magnetic resonance imaging (fMRI) both prior to treatment initiation and three months afterward. The scanning protocol will include structural T1-weighted MRI sequences (8 minutes), resting-state fMRI (4 runs of 5.5 minutes each; 22 minutes total), and task-based fMRI to assess responses to high- and low-fat food cues (2 runs of 5.5 minutes each; 11 minutes total). The imaging component will enable the investigation of treatment-related changes in functional brain connectivity associated with setmelanotide.
Time frame: Baseline to 12/24/36/48/60/72 months
Changes on hypothalamic-pituitary-gonadal axis
Hypothalamic-pituitary-gonadal axis is investigated by longitudinal measurements of testosterone and estradiol levels in blood.
Time frame: Baseline to 12/24/36/48/60/72 months
Plan to share: Undecided — Due to the nature of the study population (pediatric/vulnerable) and consent limitations, sharing of de-identified IPD is not planned at this time. Requests for data access may be considered on a case-by-case basis.
Started Jan 2023 (actual). Primary completion is estimated for Dec 2030, 95 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Setmelanotide
Bardet-Biedl Syndrome